Our journey in the US market started in 1984, when Cipla became the first Indian company to receive US FDA approval. Since then, Cipla USA Inc. (the wholly-owned US subsidiary of Cipla Ltd.) has been committed to providing patients access to high-quality drugs. Headquartered in Warren, NJ, Cipla USA employs nearly 800 people and has manufacturing units in Hauppauge, LI and Fall River, MA,.
Cipla Ltd. is a leading global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in home markets of India, South Africa, North America, and key regulated and emerging markets. With 47 manufacturing sites across the world, our portfolio includes over 1500 products with 50+ dosage forms spanning complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS and various other key therapeutic segments. Backed by six decades of lung research, Cipla has been a pioneer in inhalation therapy/respiratory care in India and several emerging markets.
Today, Cipla ranks No. 2 in inhaler sales globally and features in the Top 3 for US generic respiratory sales.
Since its inception in 1935, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. Today, Cipla is one of the most respected pharmaceutical names in India as well as across 80+ countries. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.